Download FULL DOWNLOADABLE SCHEDULE

30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
NOVEMBER 6, 2015
7 a.m. – 7:45 a.m.
State of SITC: Membership Business Meeting
All SITC 2015 attendees are welcome
7:45 a.m. – 7:50 a.m.
Presidential Welcome
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Milestones in Immunotherapy
Non-CME Session
7:50 a.m. – 8:20 a.m.
From Immune Surveillance to Personalized Cancer Vaccines
Robert Schreiber, PhD – Washington University School of Medicine
8:20 a.m. – 8:50 a.m.
Costimulation and CTLA4
James P. Allison, PhD – University of Texas MD Anderson Cancer Center
8:50 a.m. – 9:20 a.m.
Therapeutic Cancer Vaccines
Cornelis J.M. Melief, MD, PhD – Leiden University Medical Center
9:20 a.m. – 9:50 a.m.
Adoptive Cell Transfer and Neoantigens
Steven A. Rosenberg, MD, PhD – National Cancer Institute/National Institutes
of Health
9:50 a.m. – 9:55 a.m.
Questions and Answers
9:55 a.m. – 10:15 a.m.
Break
New Insights into T Cell Function
1.75 AMA PRA Category 1 Credits™
Co-Chairs:
Rafi Ahmed, PhD – Emory University
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
10:15 a.m. – 10:20 a.m.
Introduction
10:20 a.m. – 10:40 a.m.
Building Curative Anti-tumor T Cells
Nicholas P. Restifo, MD – National Cancer Institute
10:40 a.m. – 11 a.m.
Tissue Resident Memory T Cells
David Masopust, PhD – University of Minnesota
11 a.m. – 11:20 a.m.
T Cell Exhaustion
Rafi Ahmed, PhD – Emory University
11:20 a.m. – 11:40 a.m.
New Insights into CD8 Function and Regulation
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
11:40 a.m. – 11:55 a.m.
Tissue Resident Memory T Cells Create Genetically Distinct Immune
Microenvironment within Melanoma Metastasis
Kavita Dhodapkar, MD – Yale University
11:55 a.m. – Noon
Closing Remarks
Rafi Ahmed, PhD – Emory University
Late Breaking Abstract Session I
Non-CME Session
Noon – 12:15 p.m.
Late Breaking Abstract 1
12:15 p.m. – 12:30 p.m.
Late Breaking Abstract 2
12:30 p.m. – 2 p.m.
Lunch and Poster Viewing
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
Smalley Keynote
.5 AMA PRA Category 1 Credits™
2 p.m. – 2:05 p.m.
Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 p.m. – 2:30 p.m.
Smalley Keynote Presentation
Tasuku Honjo, MD, PhD –Department of Immunology and Genomic Medicine,
Graduate School of Medicine, Kyoto University
2:30 p.m. – 2:35 p.m.
Question & Answer
Tasuku Honjo, MD, PhD –Department of Immunology and Genomic Medicine,
Graduate School of Medicine, Kyoto University
Adoptive Immunotherapy
Developed in Collaboration with International Society for Cell Therapy (ISCT)
1.75 AMA PRA Category 1 Credits™
Co-Chairs:
Malcolm K. Brenner, MD, PhD – Baylor College of Medicine
Bruce Levine, PhD – Abramson Cancer Center, University of Pennsylvania
2:35 p.m. – 2:55 p.m.
Enhancing CAR-T-Cell activity via the TCR
Cliona M. Rooney, PhD – Baylor College of Medicine
2:55 p.m. – 3:15 p.m.
CARS/TCR
Stephen Grupp, MD, PhD – University of Pennsylvania
3:15 p.m. – 3:35 p.m.
Regulatory T Cells to Induce Tolerance in Hematopoletic Stem Cell
Transplantation
Bruce R. Blazar, MD – University of Minnesota
3:35 p.m. – 3:50 p.m.
Durable Complete Response in a Patient with Metastatic Melanoma Following
Adoptive Transfer of Autologous T Cells Recognizing 10 Mutated Tumor
Antigens
Todd Prickett, PhD – National Cancer Institute, National Institutes of Health
3:50 p.m. – 4:05 p.m.
A Bispecific Chimeric Antigen Receptor Molecule Enhances T Cell Activation
Through Dual Immunological Synapse Formation and Offsets Antigen Escape in
Glioblastoma
Meenakshi Hegde, MD – Baylor College of Medicine
4:05 p.m. – 4:20 p.m.
Panel Discussion
4:20 p.m. – 4:50 p.m.
Break
Concurrent Session I: Immunogenomics and Oncogenetics
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Francesco M. Marincola, MD – Sidra Medical and Research Center
Kai W. Wucherpfennig, MD, PhD – Harvard Medical School
4:50 p.m. – 4:55 p.m.
Introduction
Francesco M. Marincola, MD- Sidra Medical and Research Center
4:55 p.m. – 5:10 p.m.
Facets of Immunogenomics
Christophe Benoist, MD, PhD – Harvard Medical School
5:10 p.m. – 5:25 p.m.
In Vivo Discovery of Novel Targets for Cancer Immunotherapy
Kai Wucherpfennig, MD, PhD – Harvard Medical School
5:25 p.m. – 5:40 p.m.
Understanding the CD8 T Cell Response to Melanoma Using Transnuclear
Mouse Models
Stephanie Dougan, PhD – Dana-Farber Cancer Institute
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
5:40 p.m. – 5:55 p.m.
Toward the Identification of Genetic Determinants of Cancer Immune
Responsiveness
Davide Bedognetti, MD, PhD – Sidra Medical and Research Center
5:55 p.m. – 6:10 p.m.
From Immunogenetic Polymorphism to Functional Antitumor Lymphocyte
Mitochondrial Dynamics
Anil Shanker, PhD – Meharry Medical College School of Medicine/Vanderbilt-
Ingram Cancer Center
6:10 p.m. – 6:15 p.m.
Closing
Kai W. Wucherpfennig, MD, PhD – Harvard Medical School
Concurrent Session II: Cutting-Edge Clinical Trials
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Sandra Demaria, MD – New York University School of Medicine
Elizabeth M. Jaffee, MD – Johns Hopkins University
4:50 p.m. – 4:55 p.m.
Introduction
Sandra Demaria, MD – New York University School of Medicine
4:55 p.m. – 5:15 p.m.
PD1 Modulation in Mismatch Repair Deficient Tumors
Dung T. Le, MD – Johns Hopkins Sidney Kimmel Comprehensive Cancer
Center
5:15 p.m. – 5:35 p.m.
Targetable Immune Escape Mechanisms in Hodgkin Lymphoma
Margaret A. Shipp, MD – Dana-Farber Cancer Institute
5:35 p.m. – 5:55 p.m.
Radiotherapy as Adjuvant to Immunotherapy: Clinical Translation
Silvia Formenti, MD – New York Presbyterian/Weill Cornell Medical Center
5:55 p.m. – 6:10 p.m.
Autologous HER2 CMV Bispecific CAR T Cells are Safe and Demonstrate
Clinical Benefit for Glioblastoma in a Phase I Trial
Nabil Ahmed, MD – Baylor College of Medicine
6:10 p.m. – 6:15 p.m.
Closing Remarks
Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins University
Special Events:
6:10 p.m. – 7:30 p.m.
Poster Reception and Viewing
Prince George’s Exhibition Hall A
8 p.m. – 11 p.m.
The Check Points Party
TBD
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
NOVEMBER 7, 2015
Cancer Immunotherapy Trials Network Update
.75 AMA PRA Category 1 Credits™
7:45 a.m. – 8:35 a.m.
TBD
Coinhibition & Costimulation
1.75 AMA PRA Category 1 Credits™
Co-Chairs:
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute/Providence Medical Center
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
8:35 a.m. – 8:40 a.m.
Introduction
Andrew Weinberg, PhD – Earle A Chiles Cancer Research Institute/Providence
Cancer Center
8:40 a.m. – 9:05 a.m.
Combined Coinhibition in the Clinic
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
9:05 a.m. – 9:30 a.m.
Preclinical/Costimulation within Tumor Immunotherapy
Isabelle Le Mercier, PhD – Geisel School of Medicine at Dartmouth
9:30 a.m. – 9:50 a.m.
OX40 Agonist Agents in Pre-clinical Models
Daniel Hirschhorn-Cymerman, PhD – Memorial Sloan Kettering Cancer Center
9:50 a.m. – 10:05 a.m.
Agonist Anti-4-1 BB Plus Neutralizing Anti-CTLA-4 or –PD-L1 Synergize to
Promote Tumor Regression by Rescuing Dying Dysfunctional CD8+ T Cells
Within the Tumor Microenvironment
Brendan Horton, MD, PhD – University of Chicago
10:05 a.m. – 10:20 a.m.
Abstract 2
TBD
10:20 a.m. – 10:35 a.m.
Break
Mechanisms and Responses to Immune Therapy
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
10:35 a.m. – 10:40 a.m.
Introduction
Thomas Gajewski, MD, PhD – University of Chicago
10:40 a.m. – 11 a.m.
Antigen Identification from Patients Responding to Immunotherapy
Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute
11 a.m. – 11:20 a.m.
Understanding Responses to Therapy: the Tissue is the Issue
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer
Center
11:20 a.m. – 11:40 a.m.
Molecular Determinants of the Host Immune Response to Cancer
Thomas F. Gajewski, MD, PhD – University of Chicago
11:40 a.m. – 11:55 a.m.
Characterization of Oncogenic Pathways Linked with T Cell Exclusion in
Urothelial Bladder Cancer
Randy Sweis, MD – University of Chicago
11:55 a.m. – 12:00 p.m.
Closing Remarks
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer
Center
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
Late Breaking Abstract Session II
Non-CME Session
Noon – 12:15 p.m.
Efficacy of Anti-ICOS Agonist Monoclonal Antibodies in Preclinical Tumor
Models Provides a Rationale for Clinical Development as Cancer
Immunotherapeutics
Thomas Gajewski, MD, PhD – University of Chicago
12:15 p.m. – 12:30 p.m.
Late Breaking Abstract 1
12:30 p.m. – 12:45 p.m.
Late Breaking Abstract 2
12:45 p.m. – 2:00 p.m.
Lunch and Poster Viewing
Presidential Session
1.0 AMA PRA Category 1 Credits™
Chair:
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2 p.m. – 2:05 p.m.
Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 p.m. – 2:20 p.m.
Inhibition of the T-cell oxygen sensing machinery promotes anti-tumor efficacy
David Clever – Surgery Branch - National Institute of Health/National Cancer
Institute
2:20 p.m. – 2:35 p.m.
Selection of circulating PD-1 + lymphocytes from cancer patients enriches for
tumor-reactive and mutation- specific lymphocytes
Alena Gros, PhD – Surgery Branch - National Cancer Institute
2:35 p.m. – 2:50 p.m.
Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function
despite high PD-1 expression
Dan Erkes – Thomas Jefferson University
2:50 p.m. – 3:05 p.m.
Inhibition of fatty acid oxidation modulates immunosuppressive functions of
myeloid-derived suppressor cells and enhances cancer therapies
Amir Al-Khami, PhD – Louisiana State University Health Sciences Center
SITC Immunoscore Validation Project Update
.25 AMA PRA Category 1 Credits™
3:05 p.m. – 3:20 p.m.
SITC Immunoscore Validation Project Update
SITC Biomarkers Task Force Update
.25 AMA PRA Category 1 Credits™
3:20 p.m. – 3:35 p.m.
SITC Biomarkers Task Force Update
Lisa H. Butterfield, PhD – University of Pittsburgh
3:35 p.m. – 4:05 p.m.
Break
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
Concurrent Session: Innate Immunity
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:05 p.m. – 4:10 p.m.
Introduction
Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:10 p.m. – 4:35 p.m.
PTX3 as an Extrinsic Oncosuppressor Regulating Complement and
Macrophage Driven Inflammation
Mantovani Alberto, MD – Humanitas University
4:35 p.m. – 5 p.m.
Chimeric Endocrine Receptor-Expressing T Cells Influenced by the
Microbiodata Delay Ovarian Cancer Progression by Boosting Pre-Existing AntiTumor Immunity
Jose R. Conejo-Garcia, MD, PhD – The Wistar Institute
5 p.m. – 5:15 p.m.
Targeting KIT on Innate Immune Cells Enhances the Antitumor Activity of
Checkpoint Inhibitors in Vivo
TBD
5:15 p.m. – 5:30 p.m.
Local Immunotherapy with ONCOS-102 Shapes Harmful Tumor Associated
CD68+ Macrophages to Become Beneficial Cells that Correlate with Increased
Overall Survival
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
Concurrent Session: Precision Immunology
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Holden T. Maecker, PhD – Stanford University Medical Center
Drew M. Pardoll, MD, PhD – Johns Hopkins University School of Medicine
4:05 p.m. – 4:10 p.m.
Introduction
Holden T. Maecker, PhD – Stanford University
4:10 p.m. – 4:35 p.m.
Pre-existing Immunity and Treatment Outcome with Anti-PD1 Therapy in
Melanoma
Paul Tumeh, MD – University of California Los Angeles
4:35 p.m. – 4:55 p.m.
Epitope Signatures and Melanoma Response to CTLA4 Therapy
Timothy Chan, MD, PhD – Memorial Sloan Kettering Cancer Center
4:55 p.m. – 5:15 p.m.
PD-1 Blockade in Mismatch Repair Deficient Tumors
Luis A. Diaz, MD – Johns Hopkins Sidney Kimmel Cancer Center
5:15 p.m. – 5:30 p.m.
Dissecting the Tumor Micro-Environment in Triple Negative Breast Cancer
Identifies a Mutually Exclusive Expression Pattern of the Immune Co-Inhibitory
Molecules B7-H4 and PD-L1
Kurt Schalper, MD, PhD – Yale University
5:30 p.m. – 7 p.m.
Break
Special Events:
4:45 p.m. – 6:30 p.m.
30th Anniversary Award Ceremony
Maryland Ballroom
6:30 p.m. – 10 p.m.
Milestones and Momentum: 30th Anniversary Reception
Smithsonian National Air and Space Museum
30th Anniversary Annual Meeting
Gaylord National Hotel & Convention Center • November 6-8, 2015 • National Harbor, Maryland
NOVEMBER 8, 2015
Hot Topic Session on Value for Cancer Immunotherapy
Non-CME Session
Chairs:
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
7:45 a.m. – 7:50 a.m.
Welcome and Introductions
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
7:50 a.m. – 8 a.m.
Perspective: Biomarkers
Lisa H. Butterfield, PhD – University of Pittsburgh
8 a.m. – 8:10 a.m.
Perspective: Health Policy
TBD
8:10 a.m. – 8:15 a.m.
Perspective: Analytics/Immunotherapy
Kimberly A. Shafer-Weaver, PhD – AstraZeneca
8:15 a.m. – 8:20 a.m.
Perspective: Industry
Kevin Trapp – Bristol- Myers Squibb
8:20 a.m. – 8:25 a.m.
Perspective: Payor
Ira Klein, MD, MBA, FACP – Janssen Pharmaceuticals Company
8:25 a.m. – 8:35 a.m.
Perspective: Patient Support
Gwen Darien - Cancer Support Community
8:35 a.m. – 8:55 a.m.
Panel Discussion
8:55 a.m. – 9:15 a.m.
Audience Questions & Answer
Moderator: Peter P. Yu, MD, FACP, FASCO - Palo Alto Medical Foundation
9:15 a.m.
30th Anniversary Annual Meeting Adjourns